Latest News

STAT Plus: Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

As U.S. regulators prepare to consider whether to approve the first new treatment for Alzheimer’s disease in two decades, the latest in a long line of failures has experts taking a closer look at the field’s only purported success.

In a clinical trial, two treatments from Eli Lilly (LLY) and Roche (RHHBY) failed to help patients with a rare, inherited form of the disease, the companies said Monday. Each drug relied on the theory that targeting a toxic brain plaque called amyloid can slow cognitive decline in Alzheimer’s. And thus the focus quickly shifted to Biogen (BIIB), which made global headlines last year after claiming a controversial victory with an amyloid-targeting therapy of its own. With that treatment expected to undergo Food and Drug Administration review this year, do the results from Lilly and Roche poke holes Biogen’s case for approval?

Continue to STAT Plus to read the full story…

Source link

Related posts

TEG Architects announces new firm ownership and other news


Gene which decreases risk of social network-related stress, increases finance-related stress risk


Preemptive analgesia may cut post-op pain in anorectal surgery


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World